LifeArc backs 15 patient studies into ‘re-purposed’ therapies to fight coronavirus

£10m in grants mean patient enrolment can begin immediately Medical research charity LifeArc is providing £10m for…

LifeArc and MRC partnership creates new £16m fund to establish Gene Therapy Innovation Hubs

The Medical Research Council (MRC) and independent medical research charity LifeArc are making £16m available to establish…

LifeArc provides £2m to the University of Edinburgh STOPCOVID initiative

LifeArc provides £2m to the STOPCOVID project, which aims to test existing and experimental drugs to find a treatment for COVID-19

LifeArc launches £10 million research fund to address the challenges of COVID-19

Today, LifeArc, a UK-based medical research charity, has created a £10 million fund to support research to…

LifeArc announces seed fund investment in start-up GyreOx

The funding will support a two-year programme to develop and automate GyreOx’s proprietary drug discovery platform, MACRO.

LifeArc boosts investment in Cambridge University spin-out PolyProx Therapeutics to advance new class of cancer medicines

The investment will help advance studies to validate polyproxin® molecules as potential drug candidates across a range of cancers.

LifeArc and Scottish Government Chief Scientist Office launch new funding scheme to boost translational research in Scotland

Funding aims to progress strong discovery science to a point where additional substantive funding could be secured.

LifeArc and Action Medical Research launch funding call for research into rare diseases in children

£1m for translational research projects focussed on children’s rare diseases

LifeArc appoints new Chief Investment Officer (CIO)

Graham Duce appointed to the newly created role of CIO to ensure that we have a sustainable approach to income generation